MVX-220

MavriX Bio Doses First Patient in Landmark ASCEND-AS Gene Therapy Trial

Middleton, Massachusetts – November 6, 2025 – MavriX Bio, a clinical-stage biotechnology company focused on transformative genetic medicines, announced...

By cGxPwire Editor
November 6, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

MVX-220

MavriX Bio Doses First Patient in Landmark ASCEND-AS Gene Therapy Trial